InMed Pharmaceuticals Inc.
INM · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -244.86% | -364.96% | -328.02% | -5,930.44% |
| EV / EBITDA | 0.99 | 0.52 | 0.80 | 0.50 |
| Quality | ||||
| ROIC | -55.86% | -79.99% | -67.13% | -108.52% |
| Gross Margin | 34.53% | 23.94% | 33.93% | 49.89% |
| Cash Conversion Ratio | 0.95 | 0.91 | 0.92 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.12% | 61.60% | – | 1,028,864.62% |
| Free Cash Flow Growth | -11.03% | 6.04% | 52.35% | -59.54% |
| Safety | ||||
| Net Debt / EBITDA | 1.42 | 0.79 | 1.09 | 0.52 |
| Interest Coverage | -21.22 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.37 | 2.81 | 1.69 | 0.17 |
| Cash Conversion Cycle | 101.01 | 92.53 | 166.20 | 1,178.23 |